| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Diffractaic acid targets multiple cellular pathways involved in microbial growth, inflammation, and pain. The compound exhibits antimicrobial activity against various bacterial and fungal pathogens. Its anti-inflammatory effects are mediated through the modulation of inflammatory cytokine production and signaling pathways. The compound's analgesic activity is attributed to its ability to modulate pain signaling pathways.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Diffractaic acid exhibits antimicrobial activity as evaluated by standard disk diffusion or microdilution assays. The compound's ability to inhibit the growth of various bacterial and fungal strains can be assessed in cell-free systems. Its anti-inflammatory activity can be evaluated by measuring its effects on purified inflammatory mediators or signaling components.
|
| ln Vivo |
In mice, acetic acid-induced writhing and tail-pressure techniques demonstrate the analgesic action of fracturecylic acid[2].
In cell-based assays, Diffractaic acid exhibits antimicrobial effects by inhibiting the growth of microbial pathogens in infected cell cultures. The compound's anti-inflammatory effects are evaluated by measuring the inhibition of pro-inflammatory cytokine production in immune cells. Its analgesic activity can be assessed in neuronal cell models by measuring the modulation of pain-related signaling pathways. |
| Enzyme Assay |
The cell-free assay for antimicrobial activity involves standard disk diffusion or microdilution methods. The compound is applied to agar plates inoculated with bacterial or fungal strains, and the zone of inhibition is measured. The minimum inhibitory concentration (MIC) is determined from broth microdilution assays. Anti-inflammatory activity can be assessed using cell-free assays measuring the inhibition of inflammatory mediators or signaling components.
|
| Cell Assay |
Cell-based assays for Diffractaic acid involve culturing relevant cell lines and treating them with the compound at concentrations ranging from 0.1 to 1000 μM. Antimicrobial activity is assessed by measuring the inhibition of microbial growth in infected cell cultures. Anti-inflammatory effects are assessed by measuring cytokine production in LPS-stimulated immune cells. The compound's effects on cell viability and proliferation are assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
There is no established animal experimental protocol for Diffractaic acid specifically. As a natural lichen metabolite with antimicrobial, anti-inflammatory, and analgesic activities, the compound could potentially be evaluated in animal models of infection, inflammation, and pain. Typical studies involve administration of the compound to mice via oral or intraperitoneal routes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Diffractaic acid have not been extensively reported. As a depside with a molecular weight of approximately 374.3 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is typically metabolized by esterases and other enzymes. Further pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Diffractaic acid is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a compound with diverse biological activities, it may have effects on multiple cellular processes. Standard toxicity studies would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
4-[(2,4-dimethoxy-3,6-dimethylphenyl)-oxomethoxy]-2-hydroxy-3,6-dimethylbenzoic acid is a carbonyl compound. It has been reported to be found in Pseudocyphellaria norvegica, Ophioparma ventosa, and other organisms with relevant data.
Diffractaic acid is a research-grade natural product supplied for antimicrobial and anti-inflammatory research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a naturally occurring lichen metabolite. This product is intended for research use only. |
| Molecular Formula |
C20H22O7
|
|---|---|
| Molecular Weight |
374.38
|
| Exact Mass |
374.137
|
| CAS # |
436-32-8
|
| PubChem CID |
94870
|
| Appearance |
White to off-white solid powder
|
| Density |
1.26g/cm3
|
| Boiling Point |
604.9ºC at 760mmHg
|
| Flash Point |
214.2ºC
|
| Vapour Pressure |
1.74E-15mmHg at 25°C
|
| Index of Refraction |
1.583
|
| Source |
Originated from plants: Usneaceae Usnea diffracta Vain.
Originated from plants: Sinopteridaceae Usnea diffracta Vain. |
| LogP |
3.56
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(OC1=CC(C)=C(C(O)=O)C(O)=C1C)C2=C(C)C=C(OC)C(C)=C2OC
|
| InChi Key |
MIJKZXWOOXIEEU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H22O7/c1-9-8-14(11(3)17(21)15(9)19(22)23)27-20(24)16-10(2)7-13(25-5)12(4)18(16)26-6/h7-8,21H,1-6H3,(H,22,23)
|
| Chemical Name |
4-(2,4-dimethoxy-3,6-dimethylbenzoyl)oxy-2-hydroxy-3,6-dimethylbenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (~133.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6711 mL | 13.3554 mL | 26.7108 mL | |
| 5 mM | 0.5342 mL | 2.6711 mL | 5.3422 mL | |
| 10 mM | 0.2671 mL | 1.3355 mL | 2.6711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
